Immatics Biotechnologies GmbH of Tübingen, Germany has started vaccination of the first patients in a Phase 3 trial of its therapeutic vaccine for renal cell cancer. The primary endpoint is overall survival in combination with sunitinib. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy Research & University News
